-Abstract Highlights New Preclinical Data on Exosome-Based Delivery of PMOs for the Treatment of DMD-SAN DIEGO, Nov. 12, 2024 (GLOBE…
Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC) Carlsbad, CA,…
WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical…
Company accelerated commercialization with significant new partnerships both in the U.S. and EuropeATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Femasys…
CANOPY manuscript preprint includes six-month off-drug follow-up period that highlighted strong protection by pemivibart versus placebo in the immunocompetent Cohort…
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials,…
McNamara's extensive experience in scaling imaging and eClinical companies through organic growth and acquisition strategies brings a wealth of expertise…
Conference call will be held today, Tuesday, November 12 at 9:00 am ETCARMEL, Ind., Nov. 12, 2024 (GLOBE NEWSWIRE) --…
Cellectar broadens global manufacturing network in preparation for potential commercialization of Iopofosine I 131 in 2025INDIANAPOLIS and FLORHAM PARK, N.J.,…
MORRISTOWN, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today…